AstraZeneca forecasts 2021 growth after fourth-quarter sales beat
AstraZeneca on Thursday forecast 2021 revenue growth after the COVID-19 vaccine developer beat analysts' estimates for fourth-quarter product sales, as a wide range of therapies helped cushion the hit from the pandemic. The British drugmaker said it expects 2021 revenues to increase by a low teens percentage, with "faster growth" in core earnings to $4.75 to $5.00 per share.
AstraZeneca on Thursday forecast 2021 revenue growth after the COVID-19 vaccine developer beat analysts' estimates for fourth-quarter product sales, as a wide range of therapies helped cushion the hit from the pandemic.
The British drugmaker said it expects 2021 revenues to increase by a low teens percentage, with "faster growth" in core earnings to $4.75 to $5.00 per share. Quarterly product sales of $7.01 billion surpassed a company-compiled consensus of $6.81 billion. 2020 was a crucial year for AstraZeneca. It teamed up with the University of Oxford to develop a COVID-19 vaccine, and made its largest ever deal by buying U.S. drugmaker Alexion for $39 billion as it bet on rare-disease and immunology drugs.
The London-listed company said its forecast did not include any impact from its COVID-19 vaccine, adding it intended to break out sales from the shot beginning in the first quarter this year.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- University of Oxford
- British
- AstraZeneca
- London
- U.S.
ALSO READ
British billionaire Joe Lewis gets no prison time at sentencing for insider trading
British PM Rishi Sunak unveils GBP 35 million investment in grassroots cricket to widen participation in schools
New UK documentary examines racist attacks on British Indians
British, French troops march in historic joint parades in London and Paris in a show of solidarity
Basketball-London Lions win EuroCup thriller to make British history